Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 Phosphate Receptor Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sphingosine 1 Phosphate Receptor Modulators: Overview
Sphingolipids represent an essential class of lipids found in all eukaryotes, and strongly influence cellular signal transduction. Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P1) to express a variety of symptoms and disease patterns. Inspired by its natural substrate, an array of artificial sphingolipid derivatives has been developed to target this specific G protein–coupled receptor (GPCR) in an attempt to suppress autoimmune disorders.
Function - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
Sphingosine 1 Phosphate Receptor Modulators - Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor’s function and sequester lymphocytes in lymph nodes.
Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs Chapters
This segment of the Sphingosine 1 Phosphate Receptor Modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs
Further product details are provided in the report……..
Sphingosine 1 Phosphate Receptor Modulators: Therapeutic Assessment
This segment of the report provides insights about the different Sphingosine 1 Phosphate Receptor Modulators drugs segregated based on following parameters that define the scope of the report, such as:
Sphingosine 1 Phosphate Receptor Modulators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sphingosine 1 Phosphate Receptor Modulators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sphingosine 1 Phosphate Receptor Modulators drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 Phosphate Receptor Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sphingosine 1 Phosphate Receptor Modulators: Overview
Sphingolipids represent an essential class of lipids found in all eukaryotes, and strongly influence cellular signal transduction. Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P1) to express a variety of symptoms and disease patterns. Inspired by its natural substrate, an array of artificial sphingolipid derivatives has been developed to target this specific G protein–coupled receptor (GPCR) in an attempt to suppress autoimmune disorders.
Function - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
Sphingosine 1 Phosphate Receptor Modulators - Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor’s function and sequester lymphocytes in lymph nodes.
Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs Chapters
This segment of the Sphingosine 1 Phosphate Receptor Modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs
- Cenerimod: Idorsia Pharmaceuticals
- Sonepcizumab: Lpath
- Etrasimod: Arena Pharmaceuticals
Further product details are provided in the report……..
Sphingosine 1 Phosphate Receptor Modulators: Therapeutic Assessment
This segment of the report provides insights about the different Sphingosine 1 Phosphate Receptor Modulators drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Sphingosine 1 Phosphate Receptor Modulators
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Sphingosine 1 Phosphate Receptor Modulators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sphingosine 1 Phosphate Receptor Modulators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sphingosine 1 Phosphate Receptor Modulators drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sphingosine 1 Phosphate Receptor Modulators R&D. The therapies under development are focused on novel approaches for Sphingosine 1 Phosphate Receptor Modulators.
- Sphingosine 1 Phosphate Receptor Modulators Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Sphingosine 1 Phosphate Receptor Modulators drugs?
- How many Sphingosine 1 Phosphate Receptor Modulators drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Sphingosine 1 Phosphate Receptor Modulators?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sphingosine 1 Phosphate Receptor Modulators therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sphingosine 1 Phosphate Receptor Modulators and their status?
- What are the key designations that have been granted to the emerging drugs?
- Idorsia Pharmaceuticals
- Lpath
- Bristol-Myers Squibb
- Akaal Pharma
- Oppilan Pharma
- Boston Pharmaceuticals
- Trevena
- Corium International
- Janssen Pharmaceuticals
- Arena Pharmaceuticals
- Curadim Pharma
- Bridge Medicines
- Novartis
- Celgene Corporation
- Mitsubishi Tanabe Pharma Corporation
- LG Chem Life Sciences
- Cenerimod
- Sonepcizumab
- BMS 986104
- AKP 11
- OPL 002
- BOS 173717
- TRV 045
- Fingolimod transdermal
- Ponesimod
- Etrasimod
- CP1050
- Siponimod
- Ozanimod
- Amiselimod
- LC51-0255
Introduction
Executive Summary
Sphingosine 1 Phosphate Receptor Modulators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sphingosine 1 Phosphate Receptor Modulators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sphingosine 1 Phosphate Receptor Modulators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sphingosine 1 Phosphate Receptor Modulators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Etrasimod: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Cenerimod: Idorsia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BMS 986104: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sphingosine 1 Phosphate Receptor Modulators Key Companies
Sphingosine 1 Phosphate Receptor Modulators Key Products
Sphingosine 1 Phosphate Receptor Modulators- Unmet Needs
Sphingosine 1 Phosphate Receptor Modulators- Market Drivers and Barriers
Sphingosine 1 Phosphate Receptor Modulators- Future Perspectives and Conclusion
Sphingosine 1 Phosphate Receptor Modulators Analyst Views
Sphingosine 1 Phosphate Receptor Modulators Key Companies
Appendix
Executive Summary
Sphingosine 1 Phosphate Receptor Modulators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sphingosine 1 Phosphate Receptor Modulators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sphingosine 1 Phosphate Receptor Modulators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sphingosine 1 Phosphate Receptor Modulators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Etrasimod: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Cenerimod: Idorsia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BMS 986104: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sphingosine 1 Phosphate Receptor Modulators Key Companies
Sphingosine 1 Phosphate Receptor Modulators Key Products
Sphingosine 1 Phosphate Receptor Modulators- Unmet Needs
Sphingosine 1 Phosphate Receptor Modulators- Market Drivers and Barriers
Sphingosine 1 Phosphate Receptor Modulators- Future Perspectives and Conclusion
Sphingosine 1 Phosphate Receptor Modulators Analyst Views
Sphingosine 1 Phosphate Receptor Modulators Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sphingosine 1 Phosphate Receptor Modulators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sphingosine 1 Phosphate Receptor Modulators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sphingosine 1 Phosphate Receptor Modulators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sphingosine 1 Phosphate Receptor Modulators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
